Cannabis use and risk of prescription opioid use disorder in the United States

American Journal of Psychiatry

Volumn 175, Issue 1, 2018, Pages 47-53

  Olfson, Mark ^a   Wall, Melanie M ^a   Liu, Shang Min ^a   Blanco, Carlos ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOLISM; ARTICLE; AUSTRALIAN; CANNABIS USE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; DSM-IV; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OPIATE ADDICTION; PAIN; PAIN ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STRUCTURED INTERVIEW; TOBACCO DEPENDENCE; UNITED STATES; ANALGESIA; CANNABIS ADDICTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG CONTROL; DRUG MISUSE; FOLLOW UP; INCIDENCE; PROCEDURES; RISK ASSESSMENT; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

MEDICAL CANNABIS; NARCOTIC ANALGESIC AGENT;

ADULT; ANALGESICS, OPIOID; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG AND NARCOTIC CONTROL; DRUG MISUSE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MARIJUANA ABUSE; MEDICAL MARIJUANA; PAIN MANAGEMENT; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 85040374209     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.17040413     Document Type: Article

References (39)

1. Han B, Compton WM, Jones CM, et al: Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA 2015; 314:1468–1478
2. BlancoC,AldersonD,OgburnE,etal:ChangesintheprevalenceofnonmedicalprescriptiondruguseanddrugusedisordersintheUnitedStates: 1991–1992 and 2001–2002. Drug Alcohol Depend 2007; 90:252–260
3. Center for Behavioral Health Statistics and Quality: Key Substance Use and Mental Health Indicators in the United States: Results From the 2015 National Survey on Drug Use and Health (HHS Publication No SMA 16-4984, NSDUH Series H-51). Rockville, Md, Substance Abuse and Mental Health Services Administration, 2016
4. RuddRA,SethP,DavidF,etal:Increasesindrugandopioid-involved overdose deaths: United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65:1445–1452
5. Office of the Surgeon General: Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington, DC, US Department of Health and Human Services, Office of the Surgeon General, 2016
6. Zhang S: Patients are ditching opioid pills for weed: can marijuana help solve the opioid epidemic? Atlantic, Feb 2, 2017
7. Miller G: Could pot help solve the US opioid epidemic? Science, Nov 3, 2016
8. Bachhuber MA, Saloner B, Cunningham CO, et al: Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med 2014; 174:1668–1673
9. Powell D, Pacula RL, Jacobson M: Do medical marijuana laws reduce addictions and deaths related to pain killers? NBER Working Paper No 21345. Cambridge, Mass, National Bureau of Economic Research, 2015
10. Bradford AC, Bradford WD: Medical marijuana laws reduce prescription medication use in Medicare Part D. Health Aff (Millwood) 2016; 35:1230–1236
11. Finney JW, Humphreys K, Harris AHS: What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality. JAMA Intern Med 2015; 175:655–656
12. Boehnke KF, Litinas E, Clauw DJ: Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 2016; 17:739–744
13. Whiting PF, Wolff RF, Deshpande S, et al: Cannabinoids for medical use. JAMA 2015; 313:2456–2473
14. Hazekamp A, Heerdink ER: The prevalence and incidence of medicinal cannabis on prescription in the Netherlands. Eur J Clin Pharmacol 2013; 69:1575–1580
15. Abrams DI, Couey P, Shade SB, et al: Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90:844–851
16. Lynskey MT, Heath AC, Bucholz KK, et al: Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003; 289:427–433
17. Blanco C, Hasin DS, Wall MM, et al: Cannabis use and incidence of psychiatric disorders: prospective evidence from a national longitudinal study. JAMA Psychiatry 2016; 73:388–395
18. Grant BF, Kaplan KK, Stinson FS: Source and Accuracy Statement: The Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2007
19. Grant B, Moore T, Shepard J, et al: Source and Accuracy Statement: Wave 1 of the 2001–2002 National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). Bethesda, Md, National Institute on Alcohol Abuse and Alcoholism, 2003
20. Hasin D, Carpenter KM, McCloud S, et al: The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. Drug Alcohol Depend 1997; 44:133–141
21. Grant BF, Harford TC, Dawson DA, et al: The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend 1995; 39:37–44
22. Hasin DS, Grant BF: The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol 2015; 50: 1609–1640
23. Le Strat Y, Le Foll B: Obesity and cannabis use: results from 2 representative national surveys. Am J Epidemiol 2011; 174:929–933
24. Canino G, Bravo M, Ramírez R, et al: The Spanish Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability and concordance with clinical diagnoses in a Hispanic population. J Stud Alcohol 1999; 60:790–799
25. Grant BF, Dawson DA, Stinson FS, et al: The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression, and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend 2003; 71:7–16
26. Ware J Jr, Kosinski M, Keller SD: A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220–233
27. Rubio JM, Olfson M, Villegas L, et al: Quality of life following remission of mental disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2013; 74:e445–e450
28. Ware J, Snow K, Kosinski M, et al: SF-36 Health Survey: Manual and Interpretation Guide. Boston, New England Medical Center, Health Institute, 1993
29. Blanco C, Wall MM, Okuda M, et al: Pain as a predictor of opioid use disorder in a nationally representative sample. Am J Psychiatry 2016; 173:1189–1195
30. Hasin DS, Saha TD, Kerridge BT, et al: Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 2015; 72:1235–1242
31. Tanda G, Pontieri FE, Di Chiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276:2048–2050
32. Ellgren M, Spano SM, Hurd YL: Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 2007; 32:607–615
33. Cadoni C, Pisanu A, Solinas M, et al: Behavioural sensitization after repeated exposure to D9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl) 2001; 158:259–266
34. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al: Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend 2011; 115:120–130
35. Wilcox HC, Wagner FA, Anthony JC: Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use. Drug Alcohol Depend 2002; 66:127–135
36. Lynskey MT, Vink JM, Boomsma DI: Early onset cannabis use and progression to other drug use in a sample of Dutch twins. Behav Genet 2006; 36:195–200
37. Bonn-Miller MO, Boden MT, Bucossi MM, et al: Self-reported cannabis use characteristics, patterns, and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse 2014; 40:23–30
38. Compton WM, Han B, Hughes A, et al: Use of marijuana for medical purposes among adults in the United States. JAMA 2017; 317:209–211
39. Compton WM, Dawson D, Duffy SQ, et al: The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States. Am J Psychiatry 2010; 167:473–474